Repaglinide is an oral hypoglycemic agent primarily used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as meglitinides, which function by stimulating insulin secretion from the pancreatic beta cells in response to meals, thereby helping to lower blood glucose levels. The chemical formula of repaglinide is C27H36N2O4S, and it features a complex structure that includes a benzoic acid moiety and a cyclohexyl group. Repaglinide is characterized by its rapid onset and short duration of action, making it particularly effective for controlling postprandial blood glucose spikes. It is typically administered shortly before meals and is often used in combination with other antidiabetic medications. The substance is generally well-tolerated, but potential side effects may include hypoglycemia and gastrointestinal disturbances. As with any medication, it is essential for patients to follow their healthcare provider's guidance regarding dosage and administration to optimize therapeutic outcomes.

Repaglinide

135062-02-1: (S)-(+)-2-Ethoxy-4-[[[N-[1-(2-piperidinophenyl)-3-methylbutyl]amino]carbonyl]methyl]benzoic acid, (S)-(+)-Repaglinide, (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid, 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid, Ag-Ee 623Zw, Agee 623, Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)-, Enyglid, Eurepa, Europa 0.5, Europa 1, GlucoNorm, NovoNorm, Novolon, Prandin, Repaglinide, Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-

CAS 135062-02-1: Repaglinide

Repaglinide

Ref: 45-1600813